SGLT2 (sodium-glucose cotransporter 2) inhibitors produce a distinctive pattern of benefits
on the evolution and progression of cardiomyopathy and nephropathy, which is …

After the publication of the revised edition, therapeutic drugs described in “Future Treatment”
were approved and important evidence for pharmacologic therapy and nonpharmacologic …

SGLT2 inhibitors have emerged as a key disease-modifying therapy to prevent the
progression of chronic kidney disease (CKD). These agents prevent decline in kidney …

Aims Sodium-glucose co-transporter 2 (SGLT2) inhibitors improve cardiovascular outcomes
in diverse patient populations, but their mechanism of action requires further study. The aim …

Abstract Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce heart failure events by
direct action on the failing heart that is independent of changes in renal tubular function. In …

Aims Effective and safe decongestion remains a major goal for optimal management of
patients with acute heart failure (AHF). The effects of the sodium–glucose cotransporter 2 …

Patients with type 2 diabetes mellitus are at a higher risk of developing heart failure
compared with the healthy population. In recent landmark clinical trials, sodium-glucose co …

Aims Sodium–glucose co‐transporter 2 (SGLT2) inhibitors improve clinical outcome in
patients with heart failure (HF), but the mechanisms behind their beneficial effects are not yet …

Background SGLT2 inhibitors are a promising treatment option in patients with heart failure
and reduced ejection fraction. We aimed to investigate the effects of empagliflozin on …

Background Investigators have hypothesized that sodium-glucose cotransporter 2 (SGLT2)
inhibitors exert diuretic effects that contribute to their ability to reduce serious heart failure …